The Patent Finder

Immundiagnostik AG

14 patents currently held · Updated Nov 18, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

2
Ending by 2030
Apr 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 22, 2027
    The maintenance fee for Determination of vitamin D metabolites in dried blood (US 9,140,711) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
  • 1 fee due Oct 7, 2027
    The maintenance fee for Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients (US 10,613,101) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,943,579Osteogenic implant matrices and endosseous tooth implants with improved osteointegration properties
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,964,363Direct determination of vitamin D in serum or plasma
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,140,711Determination of vitamin D metabolites in dried blood
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,317,419Means and Methods of Measuring Parathyroid Hormone in Patients Suffering from Oxidative Stress
In force
 · High confidence
In forceHigh confidence
US 10,613,101Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,823,258In vitro diagnostic and prognosis of major adverse events in patients undergoing coronary angiography
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,253,092Medicament and Apparatus for Treating Chronic Kidney Disease
In force
 · High confidence
In forceHigh confidence
US 10,947,301Method of treating extracellular tissue and vascular calcification and arteriosclerosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,221,337Method and test kit for the quantitative determination of biomarkers in fecal samples
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,085,922Method of measuring auto-antibodies in bodily fluids
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 3 patents in force now held by others · 1 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 2 abandoned · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited